Intravitreal Bevacizumab (Avastin) for Diabetic Retinopathy: The 2010 GLADAOF Lecture

Figure 2

Changes in macular thickness with optical coherence tomography (OCT) during followup after intravitreal bevacizumab. The foveal thickness improved after 1 month, mean 1-mm central macular thickness (CMT) measurement decreased from 446.4𝜇m±154.4𝜇m to 333.75𝜇m±117𝜇m (𝑃<.001), and this overall improvement continued throughout the 24-month followup. At 3-, 6- 12- and 24-month followup were 344.7±115.3 μm, 321.7±102.7 μm, 303±89.1 μm and, 279.7±80 μm, respectively, which were significantly lower than at 1-month followup (𝑃<.001). CI: confidence interval (Reprinted with permission from Arevalo JF, Sanchez JG, Wu L, Maia M, Alezzandrini AA, Brito M, Bonafonte S, Lujan S, Diaz-Llopis M, Restrepo N, Rodríguez FJ, Udaondo-Mirete P; Pan-American Collaborative Retina Study Group. Primary intravitreal bevacizumab for diffuse diabetic macular edema the Pan-American Collaborative Retina Study Group at 24 months. Ophthalmology 2009; 116:1488-97, 1497.e1. Epub 2009 Jul 9).